Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma

BACKGROUND: The results of phase 1 and phase 2 studies suggest that nivolumab (a PD-1 checkpoint inhibitor) and ipilimumab (a CTLA-4 checkpoint inhibitor) have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab combined with i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:N Engl J Med
Autors principals: Larkin, James, Chiarion-Sileni, Vanna, Gonzalez, Rene, Grob, Jean Jacques, Cowey, C. Lance, Lao, Christopher D., Schadendorf, Dirk, Dummer, Reinhard, Smylie, Michael, Rutkowski, Piotr, Ferrucci, Pier Francesco, Hill, Andrew, Wagstaff, John, Carlino, Matteo S., Haanen, John B., Maio, Michele, Marquez-Rodas, Ivan, McArthur, Grant A., Ascierto, Paolo A., Long, Georgina V., Callahan, Margaret K., Postow, Michael A., Grossmann, Kenneth, Sznol, Mario, Dreno, Brigitte, Bastholt, Lars, Yang, Arvin, Rollin, Linda M., Horak, Christine, Hodi, F. Stephen, Wolchok, Jedd D.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5698905/
https://ncbi.nlm.nih.gov/pubmed/26027431
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1504030
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars